Talk Brief · Boards and Funds
Every AI market is quietly becoming a clinical market · Juan Vegarra
The hardest customer for AI is not the skeptic. It is the professional who is not allowed to believe you: the physician, the underwriter, the auditor, the engineer of record, anyone whose license, liability, or professional standing depends on not taking your word for it. Medicine met this customer first, which is why medicine has the most to teach every other AI market about what happens next. This talk argues that the clinical evidence bar is coming for every serious AI category, and that the companies who treat that as good news will own their markets.
Three lessons from commercializing AI in medicine, translated for any industry: why augmentation beats replacement in every market where the buyer carries liability; why the demo that amazes a conference audience actively damages trust with a professional one; and why the evidence your customer is allowed to act on matters more than the performance your model actually achieves. Then the part boards ask me to stay late for: the four questions every board should put to any AI proposal, internal or vendor, before a dollar moves.
The four questions on one page, ready for the next investment committee or product review, and a working vocabulary for the difference between a dataset and a data advantage, which is where most AI diligence quietly fails. Fund audiences also get a pattern list of the AI claims that do not survive clinical-grade scrutiny.
Board session, sixty to ninety minutes, works best as working discussion rather than lecture. Fund offsite or LP event, forty five minutes plus questions. English or Spanish. I bring no product pitch; I currently operate in this market, which is disclosed, and the talk stays at the pattern level.
Book this talk: juan@juanvegarra.com · Back to Speaking